Nama's AI scorecard currently rates Dr. Reddy's Laboratories Hold (5.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is RDY's P/E ratio?

Dr. Reddy's Laboratories trades at a trailing price-to-earnings ratio of 20.4.

What is the RDY price target?

The median analyst price target from 5 analysts is $14.71, with a range of $12.64 – $15.87.

Is RDY Shariah compliant?

Nama's AAOIFI-style screen reads Dr. Reddy's Laboratories as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Does RDY pay a dividend?

Yes — Dr. Reddy's Laboratories's dividend yield is 0.5%.

Nama Insights

Dr. Reddy's Laboratories (RDY)

Healthcare · Drug Manufacturers Specialty Generic · NYSE

Dr. Reddy's Laboratories (RDY) is a Healthcare company in the Drug Manufacturers Specialty Generic industry. It has a market capitalization of $12.43B, a trailing price-to-earnings ratio of 20.4 and a free-cash-flow yield of 1.5%. Over the most recent reported fiscal year, revenue grew 3.2% and free cash flow per share grew 52.5%. Nama's AI scorecard rates it Hold, 5.1 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Hold · 5.1/10

The sections balance. As of Nov 7, 2026.

Momentum

Lagging · -8.9% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-11.7%

How far the last close sits under the highest price of the past five years.

Market cap	$12.43B
Trailing P/E	20.4
Price / book	3.1
Price / sales	3.6
FCF yield	1.5%
Dividend yield	0.5%
Gross margin	52.3%
Operating margin	9.4%
Net margin	8.5%
Revenue growth (YoY)	+3.2%
Revenue growth (3-yr annual)	+11.0%
EPS growth (YoY)	—
FCF/share growth (YoY)	+52.5%
Beta	0.2
Exchange	NYSE
Sector	Healthcare
Industry	Drug Manufacturers Specialty Generic

RDY earnings

Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q4 2025	May 9, 2025	$0.20	$0.18	+11.6%	$881.95M
Q3 2025	Jan 23, 2025	$0.18	$0.17	+4.9%	—
Q2 2025	Nov 5, 2024	$0.17	$0.19	-10.5%	—
Q1 2025	Jul 27, 2024	$0.18	$0.18	-2.5%	—

RDY analyst price target

Median target $14.71 from 5 analysts, ranging $12.64 – $15.87.

Drug Manufacturers Specialty Generic peers

Ticker	Company	Market cap	P/E
TAK	Takeda Pharmaceutical	$67.16B	42.0
TEVA	Teva Pharmaceutical Industries	$49.72B	18.0
HLN	Haleon	$40.17B	21.3
ZTS	Zoetis	$32.81B	12.0
UTHR	United Therapeutics	$23.94B	21.2
VTRS	Viatris	$22.87B	7.8
NBIX	Neurocrine Biosciences	$16.66B	16.5
ELAN	Elanco Animal Health	$12.86B	24.3

Explore live RDY data on Nama Insights →

RDY FAQ

Is RDY a buy?: Nama's AI scorecard currently rates Dr. Reddy's Laboratories Hold (5.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is RDY's P/E ratio?: Dr. Reddy's Laboratories trades at a trailing price-to-earnings ratio of 20.4.
What is the RDY price target?: The median analyst price target from 5 analysts is $14.71, with a range of $12.64 – $15.87.
Is RDY Shariah compliant?: Nama's AAOIFI-style screen reads Dr. Reddy's Laboratories as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.
Does RDY pay a dividend?: Yes — Dr. Reddy's Laboratories's dividend yield is 0.5%.